Disease-modifying treatments in Alzheimer's disease.
作者信息
Edwards Marc, Corkill Robin
机构信息
Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK.
出版信息
J Neurol. 2023 Apr;270(4):2342-2344. doi: 10.1007/s00415-023-11602-8. Epub 2023 Feb 16.
Abstract
摘要
相似文献
1
Disease-modifying treatments in Alzheimer's disease.阿尔茨海默病的疾病修饰治疗
J Neurol. 2023 Apr;270(4):2342-2344. doi: 10.1007/s00415-023-11602-8. Epub 2023 Feb 16.
2
[Melatonin agonist: a possible disease-modifying agent for Alzheimer's disease].褪黑素激动剂：一种可能用于阿尔茨海默病的疾病修饰药物
Nihon Rinsho. 2012 Feb;70(2):349-52.
3
The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint.阿尔茨海默病疾病修饰疗法的评估：监管视角
Stat Med. 2004 Jan 30;23(2):305-14. doi: 10.1002/sim.1718.
4
Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.社论：阿尔茨海默病的疾病修饰治疗靶点，包括淀粉样 β 和tau 蛋白。
Med Sci Monit. 2021 Jul 26;27:e934077. doi: 10.12659/MSM.934077.
5
New Treatment Aimed at Preventing Alzheimer's Dementia.新疗法旨在预防老年痴呆症。
J Psychosoc Nurs Ment Health Serv. 2022 May;60(5):11-14. doi: 10.3928/02793695-20220324-02. Epub 2022 May 1.
6
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.爱丁堡共识：为阿尔茨海默病的疾病修饰疗法的出现做准备。
Alzheimers Res Ther. 2017 Oct 26;9(1):85. doi: 10.1186/s13195-017-0312-4.
7
Disease-modifying trials in Alzheimer's disease: a European task force consensus.阿尔茨海默病疾病修饰治疗试验：欧洲特别工作组共识
Lancet Neurol. 2007 Jan;6(1):56-62. doi: 10.1016/S1474-4422(06)70677-9.
8
We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development.在阿尔茨海默病药物研发中，我们不应区分对症治疗和改变疾病进程的治疗。
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S21-5. doi: 10.1016/j.jalz.2007.10.010. Epub 2007 Dec 21.
9
Delivering disease modifying treatments in Alzheimer's disease-An old age psychiatry UK perspective.在阿尔茨海默病中提供疾病修饰治疗——英国老年精神病学视角
Int J Geriatr Psychiatry. 2023 Dec;38(12):e6030. doi: 10.1002/gps.6030.
10
Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease.创造力与痴呆症：阿尔茨海默病的新兴诊断与治疗方法
CNS Spectr. 2008 Feb;13(2 Suppl 2):1-20; quiz 22.
引用本文的文献
1
Addressing Digital Disparities in Alzheimer Disease by Improving Access to Alzheimer Resources for Spanish-Speaking Latino or Latina Individuals in Los Angeles County: Mixed Methods Study.通过改善洛杉矶县说西班牙语的拉丁裔个人获取阿尔茨海默病资源的机会来解决阿尔茨海默病中的数字差距：混合方法研究
J Med Internet Res. 2025 Aug 13;27:e67147. doi: 10.2196/67147.
2
"I Want to Do Something" - Exploring What Makes Activities Meaningful for Community-Dwelling People Living With Dementia: A Focused Ethnographic Study.“我想做点什么”- 探索使社区居住的痴呆症患者的活动有意义的因素：一项聚焦的人种学研究。
Qual Health Res. 2024 Nov;34(13):1286-1302. doi: 10.1177/10497323241239487. Epub 2024 Apr 22.
3
Exploring the Remediation of Behavioral Disturbances of Spatial Cognition in Community-Dwelling Senior Citizens with Mild Cognitive Impairment via Innovative Technological Apparatus (BDSC-MCI Project): Protocol for a Prospective, Multi-Center Observational Study.通过创新技术设备探索社区轻度认知障碍老年居民空间认知行为障碍的矫治（BDSC-MCI项目）：一项前瞻性多中心观察性研究方案
J Pers Med. 2024 Feb 8;14(2):192. doi: 10.3390/jpm14020192.
4
Bio-Experiential Technology to Support Persons With Dementia and Care Partners at Home (TEND): Protocol for an Intervention Development Study.支持居家痴呆症患者及其护理伙伴的生物体验技术（TEND）：一项干预开发研究的方案
JMIR Res Protoc. 2023 Dec 29;12:e52799. doi: 10.2196/52799.
5
Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody.年龄、剂量和与血细胞膜上 TfR 的结合会影响 TfR 转运的抗体向脑部的递送。
Fluids Barriers CNS. 2023 May 11;20(1):34. doi: 10.1186/s12987-023-00435-2.
6
[Lecanemab in Alzheimer's disease: are we really before a shift in the prognosis of the disease?].[来卡奈单抗治疗阿尔茨海默病：我们真的迎来了疾病预后的转变吗？]
Rev Neurol. 2023 Mar 16;76(6):185-188. doi: 10.33588/rn.7606.2023055.
Zotero 插件